Skip Nav Destination
First Edition
Research Article May 19 2025
An Antibody-Drug Conjugate Targeting VpreB1 for the Treatment of B-cell Acute Lymphoblastic Leukemia
Research Article May 19 2025
PPARγ-induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in AML.
Research Article May 12 2025
Real world performance of the CALGB 10403 regimen in young adults in the United States
Research Article May 11 2025
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia
Martin Hutchings,Koorosh Korfi,Pau Montesinos,Armando Santoro,Hsin-An Hou,Pilar Martinez-Sanchez,Susana Vives,Sara Galimberti,Tsai-Yun Chen,Marco Frigeni,Sylvain Garciaz,Olga Salamero Garcia,Su-Peng Yeh,Karen Yee,Jordi Esteve,Ashish Bajel,Shaun Fleming,Anne Catherine Bretz,Jan Attig,Min Sun,Sina Nassiri,Tobias Rutishauser,Christian Klein,Y. May Ma,Gabriel Schnetzler,Stephanie Vauleon,Huixin Yu,Teresa Barata,Muriel Richard,Silke Simon,Heather Hinton,Nino Keshelava,Marion Subklewe
Research Article May 11 2025
Tagraxofusp, a CD123-Targeted Therapy, for Chronic Myelomonocytic Leukemia: Final Results of a Phase 1/2 Study
Research Article May 11 2025
Prognostic impact of Extranodal Disease on PET/CT in Follicular Lymphoma: Results from a Validation Study with ECOG 2408
Research Article April 25 2025
Activity of STAMP inhibitors in ABL2 rearranged Acute Lymphoblastic Leukemia is dependent on the Abl2 SH3 domain
Research Article April 25 2025
Checkpoint immunotherapy is associated with preferential activation of tumor-antigen specific CD4+ T cells in MDS.
Research Article April 25 2025
The oral CDK9 inhibitor voruciclib combined with venetoclax in patients with relapsed/refractory acute myeloid leukemia
Research Article April 25 2025
Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML
Research Article April 16 2025
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: a Real-World Experience
Malin Hultcrantz,Andriy Derkach,Hani Hassoun,Neha Korde,Kylee MacLachlan,Sham Mailankody,Dhwani Patel,Urvi A Shah,Carlyn R Tan,David J Chung,Oscar B Lahoud,Heather Landau,Michael Scordo,Gunjan L Shah,David Nemirovsky,Ross S Firestone,Theresia Akhlaghi,Tala Shekarkhand,Sergio Giralt,Alexander M Lesokhin,Saad Z Usmani
Research Article April 16 2025
Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma
Research Article April 16 2025
Outcomes of Myeloablative Allogeneic Hematopoietic Cell Transplantation with Omidubicel vs Haploidentical and Unrelated Donor Sources
Brief Report April 15 2025
Magnetic resonance spectroscopy-based detection of response to therapy targeting glutaminolysis in lymphoma
Research Article April 4 2025
A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myeloma
Brief Report April 3 2025
Reduced CD20 Expression yields Inferior Survival in Patients with B Cell Lymphoma Treated with CD20xCD3 Antibodies
Research Article March 3 2025
Phase 2 trial of daratumumab, cyclophosphamide, thalidomide and dexamethasone in newly diagnosed multiple myeloma
Edvan de Queiroz Crusoe,Joanna Suzana Leal Ribeiro dos Santos,Juliana de Andrade Santos,Herbert Henrique de Melo Santos,Allan de Souza Santos,Larissa Ferreira Lucas,Cristiane Almeida Requião de Pinna,Paula Nogueira Caldas Freire,Adriano Araujo de Jesus,Alessandro de Moura Almeida,Daniela Dourado Dutra,Marcos Fonseca Chaves,Jamile Souza Nicanor,Marco Aurelio Salvino,Maria da Gloria Bomfim Arruda,Vania Hungria,on behalf of GBRAM